Developing storyboards for regulatory inspection readiness and facilitation is a growing trend, yet the tool is shrouded in mystery for many pharma industry professionals. Storyboarding is a powerful approach for boiling down your company’s unique drug development journey into compartmentalized, positive short stories or messages that clarify pivotal points in time or scenarios. They provide a framework for creating clear messaging that can be consistently communicated by the inspection team. This is particularly needed for situations when opportunities for company growth, mitigation of existing gaps, and/or other unique compliance scenarios were self-identified and action was taken to ensure compliance and enable forward movement. They ultimately serve to remove confusion, contradiction, and on-the-spot decision-making when addressing inspection questions about the most difficult, convoluted aspects of your product’s drug development story. All companies have those; you are not alone.
Our Services
Our expertise and experience spans GxPs and therapeutic areas
We apply a broad and deep understanding of the industry, its history, the current landscape, and our vision for a healthier future to proactively address your challenges in the following areas and more:
Optimized AI Query Crafting: Enhance the quality of your AI interactions with our expert assistance. We’ll guide you in framing ChatGPT and other AI questions to yield insightful, accurate, and high-quality results.
In addition to the areas listed above, we offer an innovative full-service, plug-in QA functional model. Contact us to find out if your company is a candidate for this unique industry solution.
View our Services Menu for a detailed list of our solutions.
Go here to explore our pharmacovigilance quality and operational services.
Our Vision For You
Align compliance and corporate strategies.
- Develop a flexible framework that supports and documents compliance.
- Proactively include quality assurance expertise to ensure GxP data integrity.
Build a fit-for-purpose Quality Management System (QMS).
- Establish a practical QMS that pivots and evolves with the clinical development program.
- Institute processes that optimize resources and demonstrate oversight.
Establish a risk-based approach that establishes proof of compliance.
- Team with an expert to ensure adequate risk-based oversight.
- Build a documented compliance profile throughout the drug development process.
Establish a reliable inspection readiness approach.
- Leverage our existing inspection readiness materials.
- Deploy our innovative mock inspection approaches and activities.
Training Solutions
We offer a variety of training options in the quality and compliance space.
View our Services Menu for a detailed list of topics and options.
What Clients Are Saying
Doug Gentilcore
CEO, ARTMS Inc.
Jennifer Shingle
Director of Regulatory Affairs, Business Continuity, Standards & Training, Merck
Any company would be lucky to have the opportunity to work with PDC."
Liimu McGill
CEO, LSM Consulting
Our Leadership
Maryrose Petrizzo, with over 25 years of clinical quality and compliance experience, has demonstrated her expertise across various remote and on-site roles within emerging and established companies. She boasts a comprehensive skill set that includes quality oversight of drug, biologic, and medical device clinical trials; regulatory inspection readiness; quality systems development and implementation; risk, record, and issue management; clinical due diligence; pharmacovigilance; and Good Clinical Practices (GCP). In addition to establishing / managing clinical inspection readiness programs for FDA, EMA, and MHRA regulatory agency inspections, Maryrose has consulted for NIH / NIAID / DAIDS. Her expertise encompasses multiple therapeutic areas, including CNS, cardiology, neurology, gastroenterology, oncology, blood products, plasma, and rare diseases. Equipped with Cyntegrity Black Belt training in Risk-Based Quality Management, Maryrose offers a range of training services covering ICH E6 GCP, ISO 14155:2020, inspection readiness, mock inspection conduct, Subject Matter Expert interviews, protocol deviation management, sponsor oversight, and clinical trial risk management.